- Home
- SNCY vs CDNA Comparison
SNCY vs CDNA Comparison
Compare SNCY & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- CDNA
- Stock Information
- Founded
- SNCY 1982
- CDNA 1998
- Country
- SNCY United States
- CDNA United States
- Employees
- SNCY N/A
- CDNA N/A
- Industry
- SNCY Air Freight/Delivery Services
- CDNA Medical Specialities
- Sector
- SNCY Consumer Discretionary
- CDNA Health Care
- Exchange
- SNCY Nasdaq
- CDNA Nasdaq
- Market Cap
- SNCY 634.5M
- CDNA 712.2M
- IPO Year
- SNCY 2021
- CDNA 2014
- Fundamental
- Price
- SNCY $12.46
- CDNA $14.77
- Analyst Decision
- SNCY Buy
- CDNA Buy
- Analyst Count
- SNCY 7
- CDNA 8
- Target Price
- SNCY $18.86
- CDNA $26.86
- AVG Volume (30 Days)
- SNCY 921.2K
- CDNA 951.2K
- Earning Date
- SNCY 10-29-2025
- CDNA 11-04-2025
- Dividend Yield
- SNCY N/A
- CDNA N/A
- EPS Growth
- SNCY 28.51
- CDNA N/A
- EPS
- SNCY 1.05
- CDNA 1.00
- Revenue
- SNCY $1,106,213,000.00
- CDNA $340,826,000.00
- Revenue This Year
- SNCY $6.16
- CDNA $12.73
- Revenue Next Year
- SNCY $9.63
- CDNA $11.90
- P/E Ratio
- SNCY $11.87
- CDNA $14.81
- Revenue Growth
- SNCY 4.27
- CDNA 14.72
- 52 Week Low
- SNCY $8.10
- CDNA $10.96
- 52 Week High
- SNCY $18.59
- CDNA $26.37
- Technical
- Relative Strength Index (RSI)
- SNCY 58.21
- CDNA 51.63
- Support Level
- SNCY $10.25
- CDNA $14.23
- Resistance Level
- SNCY $11.76
- CDNA $15.18
- Average True Range (ATR)
- SNCY 0.59
- CDNA 0.64
- MACD
- SNCY 0.11
- CDNA -0.04
- Stochastic Oscillator
- SNCY 85.00
- CDNA 47.90
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.